Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

Moderna (MRNA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Scientists have developed an experimental mRNA vaccine that, when combined with existing immunotherapy drugs, could 'teach' the immune system to recog ...

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the ...

Researchers found that COVID-19 mRNA vaccines significantly increased survival in lung and skin cancer patients undergoing ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing ...

The Senate Homeland Security and Governmental Affairs Committee held a powerful hearing on vaccine injury testimonies. Among ...

The Covid-19 shot may have further-reaching benefits than previously thought, as mRNA vaccines appear to help increase the ...

Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.

A stunning new study offers early evidence that Covid-19 vaccines might have a secret superpower: a precisely timed mRNA shot ...